The firm signed a deal with Generica, a Slovakian private dietary supplements company, which intends to launch CardiaBeat in its Lipidia supplement in 2008.
CardiaBeat has rapidly been moving into new markets, and has signed distribution deals in India, Poland, Australia and South Korea. It also achieved novel foods approval in Europe.
"The regulatory approval we have received in 2007 has enabled us to present this product in the European market and to successfully establish agreements in several countries," said Michal Haim-Bravman.
Indeed, Enyzmotec has been busy expanding. Just last month it said it can produce a 99 per cent pure form of its brain health nutrient phosphatidylserine (PS).
The high PS will be available globally and forms part of its Sharp PS line of products. The high level will mean more ingredients can be added to a supplement capsule.
Enzymotec this summer announced it will build a new 200,000 sq foot research and development centre to meet "growing demand."
CardiaBeat is an extension of Enzymotec's functional oil formulation MultOil. This has been shown to potentially reduce the risk for coronary heart disease through preventing and controlling oxidative stress, reducing total cholesterol and triglyceride levels and inhibiting the atherosclerotic plaque formation cascade.
Enzymotec said this means it tackles more heart health indicators than many ingredients on the market, which look only after cholesterol management.
CardiaBeat also enhances the impact of plant sterols and omega-3s on cardiovascular disease (CVD) risk reduction, the firm added.
In August Enzymotec said a new R&D centre, due to be completed by the end of the year, will help the company to meet increasing demand for its products.
